Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. (Q37670334)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

enzyme replacement therapy

8 March 2020

main subject

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Nurcan Üçeyler

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

15

Stefan-Martin Brand

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

8

Claudia Sommer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Frank Weidemann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Thomas Duning

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Malte Lenders

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sima Canaan-Kühl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alice Krebs

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Hans Guerrero González

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Markus Niemann

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefan Störk

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Michael Schelleckes

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefanie Reiermann

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jörg Stypmann

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Christoph Wanner

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Eva Brand

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

20 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American Society of Nephrology

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

837-849

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

8 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

A new equation to estimate glomerular filtration rate

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Agalsidase alfa and kidney dysfunction in Fabry disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

The case for using albuminuria in staging chronic kidney disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Grading the severity of chronic pain

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

A validated disease severity scoring system for Fabry disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3968503

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

3 December 2018

1 reference

12 December 2020

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

1 reference

12 December 2020

Microalbuminuria as an early marker for cardiovascular disease

1 reference

12 December 2020

1 reference

12 December 2020

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1681/ASN.2013060585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556354%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference